Baricitinib (LY3009104) 4 mg

DRUG3 trials

Sponsors

Aaron R. Mangold, University Hospital, Toulouse, Stanford University

Conditions

Cardiac SarcoidosisCutaneous Lichen PlanusRhumatoid Arthisis

Phase 2

Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus

CompletedNCT05188521

Aaron R. MangoldCutaneous Lichen Planus

Start: 2022-01-11End: 2023-05-17Updated: 2024-06-11

A Trial of Baricitinib in Patients With Cardiac Sarcoidosis

Not yet recruitingNCT06868381

Stanford UniversityCardiac Sarcoidosis

Start: 2026-04-01End: 2028-12-01Target: 10Updated: 2026-02-10

Phase 4

JAK Inhibitor Dose TAPering Strategy Study

Not yet recruitingNCT06687551

University Hospital, ToulouseRhumatoid Arthisis

Start: 2025-01-01End: 2029-04-01Target: 308Updated: 2024-11-13

Related Papers

Repurposing the composite assessment of index lesion severity scoring system in cutaneous lichen planus.

2025-02-14

Rapid response of lichen planus to baricitinib associated with suppression of cytotoxic CXCL13+CD8+ T cells

Journal of Clinical Investigation2024-11-148 citations